As financial markets enter November 2025, investors are grappling with heightened volatility driven by lingering uncertainties around Federal Reserve policy, geopolitical tensions, and a mixed earnings season. The S&P 500 has shown resilience, posting modest gains amid rate cut expectations, but narrow market breadth—dominated by mega-cap tech—signals potential pullbacks. Inflation remains sticky near 2.5%, while GDP growth slows to around 1.8% annually, creating a challenging backdrop for broad-based advances. In such an environment, selective stock picking becomes crucial, focusing on companies with strong fundamentals, growth catalysts, and defensive moats. This article highlights five promising stocks to consider buying this month, each offering potential upside through innovation, undervaluation, or momentum. These picks span sectors like technology, healthcare, and finance, aiming to balance risk and reward in volatile times.
Applied Digital (APLD) stands out as a compelling growth play in the burgeoning AI infrastructure space. As a fast-growing operator of AI data centers, the company is capitalizing on explosive demand from hyperscalers, with industry estimates projecting $350 billion in spending on such facilities in 2025 alone. APLD’s recent partnership expansions, including a 150-megawatt lease at its Polaris Forge 1 campus with CoreWeave, have boosted its contracted revenue pipeline to approximately $11 billion over 15 years. The firm is also developing a new 200-megawatt Polaris Forge 2 campus and engaging in advanced talks with major clients, potentially scaling leased capacity to 600 megawatts across sites. Financially, APLD reported an 84% revenue surge to $64.2 million in its fiscal Q1 2026, surpassing expectations by $14.2 million, though profitability remains a work in progress amid rapid expansion. Analysts see significant upside if the company continues beating targets and raising guidance, leveraging its competitive edge in high-demand locations. With shares trading around $35.90 as of late October, APLD could deliver substantial gains for investors betting on AI’s long-term proliferation, especially as demand is expected to persist through at least 2026. This positions it as a high-reward option in volatile markets, where tech infrastructure plays often outperform during economic uncertainty.
Broadcom (AVGO) offers another attractive opportunity in the AI semiconductor arena, where it provides cost-effective alternatives to dominant players like Nvidia. The company’s custom AI accelerators boast three to five times better performance-per-watt efficiency and lower per-unit costs, appealing to hyperscalers such as Google, Meta, and ByteDance. Holding a 65% revenue share in application-specific integrated circuits for these clients, Broadcom recently secured a $10 billion order for its Titan AI inference chip from a fourth major customer, believed to be OpenAI, with production ramping up in fiscal Q3 2026 but potential early revenue in Q4 2025. Earnings momentum is strong, with Q3 fiscal 2025 AI semiconductor revenue up 53% to $5.2 billion, marking eight consecutive quarters of exceeding Wall Street forecasts—often triggering 10% to 20% stock pops post-earnings. Shares, priced at about $349.24 in late October, reflect this growth trajectory, supported by a 22% overall revenue increase in Q2 2025. In November’s uncertain climate, AVGO’s diversified chip portfolio and new design wins could drive shares higher, offering investors exposure to AI without the premium valuations of peers, potentially yielding double-digit returns if guidance is raised amid sustained hyperscaler spending.
Shifting to healthcare, Eli Lilly (LLY) emerges as a powerhouse in pharmaceuticals, fueled by its leadership in diabetes and obesity treatments. Commanding roughly 57% of the U.S. incretin market, Lilly outpaces rivals like Novo Nordisk with blockbuster drugs Mounjaro and Zepbound, which saw sales jump 68% to $5.2 billion and 172% to $3.4 billion, respectively, in Q2 2025. The company’s pipeline adds further upside, including the obesity drug retatrutide, slated for late-2025 trial results, and the newly approved Alzheimer’s therapy donanemab (Kisunla), which could accelerate revenue beyond expectations. Lilly’s Q2 revenue climbed 38% to $15.56 billion, with net income soaring 91% to $6.7 billion, prompting an upward revision to full-year 2025 guidance of $60 billion to $62 billion in revenue and EPS of $21.75 to $23.00—surpassing analyst views. Priced around $808.96, shares have shown relative stability in 2025, with lower volatility compared to tech peers, making LLY a defensive growth pick for November. As demand for weight-loss therapies surges amid global health trends, potential earnings beats could propel the stock, offering 20-30% upside in a market prone to rotations toward reliable earners.
Universal Health Services (UHS) provides a momentum-driven entry in the healthcare services sector, benefiting from robust demand for hospital and behavioral health facilities. As one of the largest U.S. providers, UHS operates 29 acute care hospitals, 331 behavioral health centers, and numerous outpatient sites, alongside insurance and physician networks. The stock has climbed 21% year-to-date through late October, outpacing its industry by a wide margin, and boasts an 820% return over the past 20 years versus the sector’s 200%. Earnings projections are optimistic, with adjusted EPS expected to grow 24% in 2025 and 7% in 2026, building on 50% bottom-line expansion this year. A recent Q3 beat-and-raise report on October 27, coupled with a $1.5 billion stock repurchase authorization boost, underscores its financial health. Trading at a 15% discount to its industry average and 52% below consensus price targets on a 9.8x forward earnings multiple, UHS is well-positioned for breakouts, especially as it nears September highs. In volatile November markets, where healthcare often serves as a safe haven, UHS’s strong momentum score and value metrics make it an appealing buy for potential near-term gains.
Rounding out the list, DexCom (DXCM) represents an undervalued gem in medical technology, particularly in continuous glucose monitoring for diabetes management. Shares are currently trading at $58.22, well below an estimated fair value of $113.90, implying a nearly 49% discount based on cash flow analyses. The company’s innovative devices, like the G7 sensor, have driven market share gains amid rising global diabetes prevalence, with revenue growth supported by expanded insurance coverage and international expansion. Despite recent pressures from competitive dynamics, DexCom’s fundamentals remain solid, with analysts forecasting earnings recovery and margin improvements as adoption accelerates. In a sector where healthcare spending is resilient to economic slowdowns, DXCM’s undervaluation offers a margin of safety, potentially yielding significant appreciation if November’s earnings season highlights positive revisions. This makes it a strategic pick for investors seeking bargains in growth-oriented health tech during market turbulence.
In summary, these five stocks—APLD, AVGO, LLY, UHS, and DXCM—offer a diversified approach to navigating November 2025’s volatility. Each benefits from sector tailwinds, whether AI-driven innovation, pharmaceutical breakthroughs, or healthcare stability, with potential for outsized gains amid broader market uncertainties. Investors should conduct due diligence, considering factors like interest rate trajectories and geopolitical risks, but these picks align with trends favoring quality growth and value. By focusing on companies with proven catalysts and attractive valuations, portfolios can be positioned for resilience and upside in the months ahead.
